Page results
-
A guide to wigs and other headwear for UCLH patients.
-
CAR T-cell therapy is a cutting-edge treatment for certain blood cancers, offering new hope to patients whose illness hasn’t responded to standard treatments. University College London Hospitals (UCLH) is proud to be one of Europe’s leading centres for this advanced care.
-
At University College Hospital education is provided for inpatients of school age on the paediatric floor (T11) and the adolescent floor (T12).
-
Our non-emergency patient transport service is provided by G4S. G4S may use approved external sub-contractors to meet the demand of the service and/or the specific needs of our patients.
-
The cochlear implant programme was founded in 1982, and we were the first clinical cochlear implant programme in the UK. The team has been involved with the successful implantation of more than 2,000 patients, both adults and children, from all over the UK.
-
UCLH provides an audiological service for GPs who would like to refer patients for age related audiological assessments.
-
The snoring and sleep disorders clinic offers, out-patient consultation including flexible endoscopy to assess upper airway collapse. Multidisciplinary team involvement for planning treatment.
-
The specialist allergy and clinical immunology service deals with the diagnosis and management of allergies and related immune system disorders in adults.
-
Information about the autogenic training service at the Royal London Hospital for Integrated Medicine.
-
Information about psychological therapy services at the Royal London Hospital for Integrated Medicine.
File results
-
FOI/2023/0635 - Redundancy consultation
-
FOI/2023/0623 - BMA rate card rates
-
FOI/2023/0617 - Neonatal unit CCTV
-
FOI/2023/0615 - Wayfinding strategy
-
FOI/2023/0613 - Treatment for Melanoma
-
FOI/2023/0578 - Spinal Muscular Atrophy (SMA) patients
-
FOI/2023/0581 - Treatment of Haemophilia
-
FOI/2023/0579 - Procurement for specialist seating for patients
-
FOI/2023/0586 - Children treated for E-scooter injuries
-
FOI/2023/0569 - Treatment for Ruxolitinib